The production volume of the locally made heart disease drug will fully cover the demand of the Russian market.
Bayer International Group will allocate USD 5 million for financing the work of the educational and research center for plant biotechnology established in Russia at the Skolkovo Institute of Science and Technology (Skoltech).
Bayer, a German pharmaceutical company, and OOO Makiz-Pharma plan to annually produce 8.5 mn packages of drugs for the treatment of osteoarthritis and osteochondrosis, prevention of calcium deficiency and symptomatic treatment of acute respiratory infections and colds in children at the facilities of the Russian pharmaceutical manufacturer. The manufacture will be a full-cycle process with the drugs sold in Russia and the CIS countries. According to the joint press release of the companies received by Pharmatsevtichesky Vestnik, the five-year contract provides for market expansion and further renewal of the agreement.
Bayer and Polysan announced the start of commercial production of the original Iopromide contract medium for tomography. The product will be produced on a full cycle at the facilities of the Russian manufacturer in St. Petersburg.
International chemical and pharmaceutical corporation Bayer launched production of diagnostic radiopaque preparations at the site of Polysan Scientific & Technological Pharmaceutical Company in Saint Petersburg, Interfax journalist reported from the ceremonial launch.
In particular, production of Gadovist, Magnevist and Ultravist preparations was organized at the facilities of Polysan. The preparations are used for diagnostics in computer and magnetic resonance tomography.
Besides, on Wednesday general representative of Bayer in Russia and CIS Niels Hessman told the journalists that the company intends to expand the portfolio of drugs localized in Russia and hopes to conclude an agreement with a local partner on localization of cancer drugs in Russia this year.
Earlier Bayer localized drugs production at the facilities of Urals Medsynthesis. In particular, in August 2015, production of anti-infective Avelox was launched.
Today, Bayer has inaugurated its seed treatment center based on Zarechie farmership in Krasnodar with a capacity up to 5 thousand seed material per season. It is the first disinfecting center founded within the framework of the program for implementation of innovative seed treatment processes in the Russian market implying transfer of hi-tech disinfecting equipment to leading farmerships of this country. Total investments since 2016 until 2017 will stand at RUB 100 m, according to the company's Press service.
German chemical and pharmaceutical corporation Bayer will continue localizing production in Russia in the next three to five years, Niels Hessmann, Bayer’s general representative in the CIS and CEO of CJSC Bayer, said to RIA Novosti.
“Providing Russia with innovative pharmaceutical and agricultural products is an important mission for Bayer in Russia. Localization is a strategic path forward in the concern’s development that reasserts Bayer’s support of the Pharma 2020 strategy formulated by the Russian government,” he noted.
“The concern’s strategic plans for the next 3-5 years are to increase that share of products manufactured in Russia,” Hessmann said.
Bayer completed its first localization project in 1995. In association with the Federal Animal Healthcare Center, the company localized production of pet supplies, followed by localization of manufacturing of agricultural products in 2003. In November 2012, the concern signed a cooperation agreement with Medsintez company. In 2015, Bayer manufactured the first commercial batch of Avelox anti-infective at Novouralsk plant.
In summer this year, the company signed a strategic partnership agreement with Polisan from Saint Petersburg. The plan is to start manufacturing contrast agents for radiographic and MRI applications at Polisan plant in 2017.
The global Bayern group plans to localize the production of test strips for glucose meters in partnership with the St. Petersburg-based Geropharm, the St. Petersburg company’s press service reported. Glucose meters are an indispensable element of home blood glucose monitoring for patients with diabetes. Geropharm specializes in diabetes medications, but it has never produced any self-monitoring products, such as glucose meters and test strips for them, before.
In spring 2015, according to a report by Rossiyskaya Gazeta, an agreement regarding the production of test strips for glucose meters in Russia was signed by LifeScan (Johnson & Johnson) and Pharmstandard. Under that agreement, the launch is expected in the third quarter of 2015. Bayer is also looking for a partner to localize the production of its glucose meters as well, RBC St. Petersburg new portal said citing a source in the city’s pharmaceutical market. Specifically, an offer to this purpose was extended to Polysan, with which Bayer had recently signed a production contract.
According to the Russian Diabetes Association, more than 4 million people in Russia have been diagnosed with type 1 or 2 diabetes. Each of them needs to monitor their blood glucose level at least once a day (or much more often in the case of type 1 diabetes) using test strips.
The Medsintez plant in Novouralsk has started serial production of a new anti-infectious medicine that will fully replace imported products. By 2016, the company plans to produce 300 thousand packets of the antibiotic, which will make it possible to fully meet demand for this medicine, said the Governor’s Information Policy Department.
“Latest-generation antibiotics killing all the known strains of microorganisms are not produced in Russia today. As a result of cooperation with Bayer AG, the plant possesses modern technologies for producing European-level medicines. Our country experiences for the first time setting up such a sophisticated production facility”, said Aleksandr Petrov, Chairman of the Supervisory Council of the Ural Biomedical Cluster, member of the State Duma Healthcare Committee.
He said that the first batch will amount to 9 thousand packets. By the end of this year, the plant will produce 150 thousand packets and 300 thousand ones in 2016. “Such quantities will make it possible to 100% meet demand of the Russian market for such medicines. Russian citizens will soon be able to purchase a latest-generation antibiotic at a moderate price”, he added.
Germany-based Bayer AG, a chemical and pharmaceutical company, has announced plans to further expand its business in Russia.
Bayer plans to increase sales by 80 per cent from their 2012 level to $1.7 billion by 2017. At the same time, the number of staff is expected to grow from 1,570 in 2012 to 2,400 in 2017 an increase of more than 800 jobs.
"We are committed to Russia as a partner and want to continue to offer valuable contributions to the development in this country, both in business and in the Russian community," Bayer Chief Executive Dr Marijn Dekkers said at a press conference.
Bayer innovations and know-how will support Russia's goals under the current government programs. "The middle class, which is an incremental driver of overall consumption, is rapidly expanding. This trend is expected to continue and plays out for industry sectors relevant to Bayer," said Dekkers.
Company's website: https://www.bayer.com
T: +49 214 30-1
Contact: Dr Marijn Dekkers, Chairman of the Board of Directors
Bayer is an international concern specialized in healthcare, agriculture, and high-tech materials.